Skip to content

Drug interactions

Dipyridamole + Vorapaxar

Severity: Major

Dipyridamole and Vorapaxar: major interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Vorapaxar is a PAR-1 antagonist with antiplatelet action and carries a labeled bleeding risk. Combining it with dipyridamole, another antiplatelet agent, increases the likelihood of bleeding, including serious bleeding.

What this interaction means in plain words

Dipyridamole and Vorapaxar can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Evidence level: Moderate

Why it happens

Additive inhibition of platelet function through different pathways (PAR-1 antagonism and adenosine reuptake/phosphodiesterase inhibition).

What to do

Avoid the combination where possible; if used, monitor closely for bleeding and reassess the need for each antiplatelet agent regularly.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Dipyridamole and Vorapaxar, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Dipyridamole with Vorapaxar?

MediHelp rates the interaction as major. Dipyridamole and Vorapaxar can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Vorapaxar is a PAR-1 antagonist with antiplatelet action and carries a labeled bleeding risk. Combining it with dipyridamole, another antiplatelet agent, increases the likelihood of bleeding, including serious bleeding.

How serious is the interaction between Dipyridamole and Vorapaxar?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination where possible; if used, monitor closely for bleeding and reassess the need for each antiplatelet agent regularly.

What other medicines interact with Dipyridamole?

MediHelp also lists interactions of Dipyridamole with, for example, Riociguat, Adenosine, Betrixaban. The full list is on the Dipyridamole page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in